CTAS vs REPL · P/E 51, rev $10.34B vs $825.7M cap
Cintas Corporation (CTAS) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported CTAS revenue for 2025-05-31 was $10.34B. Net income was $1.81B. Revenue was up 7.7% from 2024-05-31 to 2025-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
REPL does not have a complete income-statement cache yet.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. REPL currently screens at market cap $825.7M.
Not investment advice. Open the CTAS and REPL stock pages for the full models.
Not investment advice.